A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma

被引：0
|
作者：
Rosenzweig, Michael [1 ]
Sanchez, James [1 ]
Chowdhury, Arnab [1 ]
Nathwani, Nitya [1 ]
Janakiram, Murali [1 ]
Htut, Myo [1 ]
Sahebi, Firoozeh [1 ]
Walker, Tricia [1 ]
Pichiorri, Flavia [1 ]
Palmer, Joycelynne [1 ]
Krishnan, Amrita [1 ]
Keats, Jonathan [1 ,2 ]
Rosen, Steven [1 ]
机构：
[1] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[2] Translat Genom Res Inst, Duarte, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-214
引用
收藏
页码：S153 / S153
页数：1
相关论文
共 50 条
  • [1] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
  • [2] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
    Mark, Tomer M.
    Forsberg, Peter A.
    Rossi, Adriana C.
    Pearse, Roger N.
    Pekle, Karen A.
    Perry, Arthur
    Boyer, Angelique
    Tegnestam, Linda
    Jayabalan, David
    Coleman, Morton
    Niesvizky, Ruben
    [J]. BLOOD ADVANCES, 2019, 3 (04) : 603 - 611
  • [3] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    [J]. Blood Cancer Journal, 8
  • [4] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Sivaraj, Dharshan
    Green, Michael M.
    Kang, Yubin
    Long, Gwynn D.
    Rizzieri, David A.
    Li, Zhiguo
    Garrett, Anderson H.
    McIntyre, Jackie L.
    Chao, Nelson J.
    Gasparetto, Cristina
    [J]. BLOOD CANCER JOURNAL, 2018, 8
  • [5] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2014, 124 (21)
  • [6] Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Richardson, Paul G.
    Htut, Myo
    Gasparetto, Cristina
    Zonder, Jeffrey A.
    Martin, Thomas G., III
    Chen, Janice
    Brooks, Christopher
    McDonald, Peter
    Rupprecht, Nicole
    Wysowskyj, Halyna
    Chauhan, Dharminder
    Ray, Arghya
    Anderson, Kenneth C.
    Paba-Prada, Claudia E.
    [J]. BLOOD, 2019, 134
  • [7] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Amrita Krishnan
    Prashant Kapoor
    Joycelynne M. Palmer
    Ni-Chun Tsai
    Shaji Kumar
    Sagar Lonial
    Myo Htut
    Chatchada Karanes
    Nitya Nathwani
    Michael Rosenzweig
    Firoozeh Sahebi
    George Somlo
    Lupe Duarte
    James F. Sanchez
    Daniel Auclair
    Stephen J. Forman
    Jesus G. Berdeja
    [J]. Leukemia, 2018, 32 : 1567 - 1574
  • [8] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    Krishnan, Amrita
    Kapoor, Prashant
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Kumar, Shaji
    Lonial, Sagar
    Htut, Myo
    Karanes, Chatchada
    Nathwani, Nitya
    Rosenzweig, Michael
    Sahebi, Firoozeh
    Somlo, George
    Duarte, Lupe
    Sanchez, James F.
    Auclair, Daniel
    Forman, Stephen J.
    Berdeja, Jesus G.
    [J]. LEUKEMIA, 2018, 32 (07) : 1567 - 1574
  • [9] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    [J]. BLOOD, 2017, 130 (08) : 974 - 981
  • [10] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
12345